Disease: metastatic cutaneous melanoma  
Treatment: anti-PD-1 immunotherapy  
SourceName: plasma samples  
NumberOfSamples: 24  
Disease: metastatic CM  
AssayName: mass-spectrometry-based global proteomics  
AssayName: HiRIEF LC-MS/MS  
AssayName: proximity extension assays (PEAs)  
Treatment: mitogen-activated protein kinase inhibitors (MAPKis)  
FactorValue: PFS  
NumberOfSamples: 46  
Time: pre-trm  
Time: trm  
Treatment: first-line ICIs  
Treatment: anti-CTLA-4  
Treatment: anti-PD-1  
Treatment: MAPKis  
Treatment: MEKis  
Treatment: BRAFis  
TumorStage: stage IV  
Disease: metastatic (stage IV) CM  
Temperature: −70°C  
Depletion: Agilent Plasma 14 Multiple Removal System 4.6×100  
Instrument: Agilent HPLC system  
AssayName: Bio-Rad DC Assay  
CleavageAgent: LysC  
CleavageAgent: trypsin  
FactorValue: pH 8.5  
Compound: triethylammonium bicarbonate buffer, pH 8.5  
Label: isobaric tandem masstags (Thermo Scientific)  
AssayName: liquid chromatography–mass spectrometry (LC-MS/MS)  
EnrichmentMethod: solid phase extraction (SPE strata-X-C, Phenomenex)  
FractionationMethod: peptide IEF-IPG (isoelectric focusing by immobilized pH gradient)  
FactorValue: pI range 3–10  
MaterialType: 24 cm linear gradient IPG strip (GE Healthcare)  
FactorValue: 1% IPG pharmalyte pH 3–10 (GE Healthcare)  
FractionIdentifier: 72 contiguous fractions  
Compound: MilliQ water/35% acetonitrile/35% acetonitrile and 0.1% formic acid  
Instrument: IPG extractor robotics (GE Healthcare Biosciences AB, prototype instrument)  
MaterialType: 96-well plate (V-bottom, Greiner product no 651201)  
Temperature: −20°C  
AssayName: PEAs  
AssayName: Olink ImmunoOnc I panel  
SupplementaryFile: online supplementary table S0  
FactorValue: normalized protein expression values